Soligenix

Soligenix Equity Ratio

The Equity Ratio of Soligenix (SNGX) as of Oct 16, 2026 is 57.30 %. In the previous year, Equity Ratio was 45.93 % — a change of 24.77% (higher).

Equity Ratio

57.30 %

YoY

24.77%

Last updated:

Equity Ratio of Soligenix is 2025 57.30 % . Equity Ratio of Soligenix was 2024 45.93 % . It decreases by 24.77% higher compared to the previous year.

The Soligenix Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
59.86 USD
Jan 1, 2019
18.74 USD
Jan 1, 2020
18.81 USD
Jan 1, 2021
39.91 USD
Jan 1, 2022
-17.30 USD
Jan 1, 2023
25.75 USD
Jan 1, 2024
45.93 USD
Jan 1, 2025
57.30 USD
The Soligenix Equity Ratio history
YEAREquity RatioYoY
57.30 %+24.77%
45.93 %+78.39%
25.75 %-248.79%
-17.30 %-143.36%
39.91 %+112.13%
18.81 %+0.38%
18.74 %-68.69%
59.86 %-9.55%
66.18 %-8.15%
72.05 %-29,169.18%
-0.25 %-88.80%
-2.21 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Soligenix Stock analysis

What does Soligenix do? Soligenix Inc, trading under the ticker SNGX, is a biotechnology company based in Princeton, New Jersey. The company has an IPO date of April 4, 1994, and currently employs 13 people. Soligenix operates in the health care sector, specifically within biotechnology. The company focuses on developing and commercializing treatments for rare diseases. Its business segments include Specialized BioTherapeutics and Public Health Solutions. Under Specialized BioTherapeutics, Soligenix is developing SGX301, a photodynamic therapy using topical synthetic hypericin activated by visible light for cutaneous T-cell lymphoma (CTCL). The Public Health Solutions segment encompasses development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate targeting antibiotic-resistant and emerging infectious diseases. The company also references CTCL as an innate defense regulator technology, though this appears to be a misstatement as CTCL is a disease, not a technology. Soligenix's website is https://www.soligenix.com/. Soligenix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Soligenix stock

Equity Ratio of Soligenix is 57.30 % in 2025.

Equity Ratio of Soligenix changed from 45.93 % to 57.30 %, representing a 24.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Soligenix since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Soligenix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Soligenix

All Key Metrics — Soligenix